• 1
    [No authors listed.] National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982; 49: 21122135.
  • 2
    Jaffe ES,Harris NL,Stein H,Vardiman JW. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
  • 3
    Patte C,Philip T,Rodary C, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol. 1991; 9: 123132.
  • 4
    Schwenn MR,Blattner SR,Lynch E,Weinstein HJ. HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol. 1991; 9: 133138.
  • 5
    Murphy SB,Bowman WP,Abromowitch M, et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol. 1986; 4: 17321739.
  • 6
    Brecher ML,Schwenn MR,Coppes MJ, et al. Fractionated cylophosphamide and back to back high dose methotrexate and cytosine arabinoside improves outcome in patients with stage III high grade small non-cleaved cell lymphomas (SNCCL): a randomized trial of the Pediatric Oncology Group. Med Pediatr Oncol. 1997; 29: 526533.
  • 7
    Bowman WP,Shuster JJ,Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric Oncology Group study. J Clin Oncol. 1996; 14: 12521261.
  • 8
    Reiter A,Schrappe M,Ludwig WD, et al. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of 3 consecutive studies of the BFM group. Blood. 1992; 80: 24712478.
  • 9
    Magrath IT,Janus C,Edwards BK, et al. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood. 1984; 63: 11021111.
  • 10
    Patte C,Auperin A,Michon J, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001; 97: 33703379.
  • 11
    Cairo MS,Sposto R,Perkins SL, et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience. Br J Haematol. 2003; 120: 660670.
  • 12
    Reiter A,Schrappe M,Parwaresch R, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage—a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 1995; 13: 359372.
  • 13
    Magrath I,Adde M,Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996; 14: 925934.
  • 14
    Anderson JR,Jenkin RD,Wilson JF, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol. 1993; 11: 10241032.
  • 15
    Dahl GV,Rivera G,Pui CH, et al. A novel treatment of childhood lymphoblastic non-Hodgkin's lymphoma: early and intermittent use of teniposide plus cytarabine. Blood. 1985; 66: 11101114.
  • 16
    Patte C,Kalifa C,Flamant F, et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol. 1992; 20: 105113.
  • 17
    Wollner N,Burchenal JH,Lieberman PH,Exelby P,D'Angio G,Murphy ML. Non-Hodgkin's lymphoma in children. A comparative study of 2 modalities of therapy. Cancer. 1976; 37: 123134.
  • 18
    Tubergen DG,Krailo MD,Meadows AT, et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. J Clin Oncol. 1995; 13: 13681376.
  • 19
    Sullivan MP,Boyett J,Pullen J, et al. Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded). Cancer. 1985; 55: 323336.
  • 20
    Hvizdala EV,Berard C,Callihan T, et al. Lymphoblastic lymphoma in children—a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group study. J Clin Oncol. 1988; 6: 2633.
  • 21
    Sandlund JT,Santana V,Abromowitch M, et al. Large cell non-Hodgkin lymphoma of childhood: clinical characteristics and outcome. Leukemia. 1994; 8: 3034.
  • 22
    Sandlund JT,Pui CH,Santana VM, et al. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma. J Clin Oncol. 1994; 12: 895898.
  • 23
    Sandlund JT,Pui CH,Roberts WM, et al. Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood. 1994; 84: 24672471.
  • 24
    Kadin ME. Ki-1/CD30+ (anaplastic) large-cell lymphoma: maturation of a clinicopathologic entity with prospects of effective therapy [editorial]. J Clin Oncol. 1994; 12: 884887.
  • 25
    Stansfeld AG,Diebold J,Noel H, et al. Updated Kiel classification for lymphomas. Lancet. 1988; 1: 292293.
  • 26
    Kadin ME. Ki-1-positive anaplastic large-cell lymphoma: a clinicopathologic entity? J Clin Oncol. 1991; 9: 533536.
  • 27
    Stein H,Mason DY,Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985; 66: 848858.
  • 28
    Sposto R,Meadows AT,Chilcote RR, et al. Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: a report from the Children's Cancer Group. Med Pediatr Oncol. 2001; 37: 432441.
  • 29
    Weinstein HJ,Lack EE,Cassady JR. APO therapy for malignant lymphoma of large cell “histiocytic” type of childhood: analysis of treatment results for 29 patients. Blood. 1984; 64: 422426.
  • 30
    Hvizdala EV,Berard C,Callihan T, et al. Nonlymphoblastic lymphoma in children—histology and stage-related response to therapy: a Pediatric Oncology Group study. J Clin Oncol. 1991; 9: 11891195.
  • 31
    Laver JH,Mahmoud H,Pick TE, et al. Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma. 2001; 42: 399405.
  • 32
    Santana VM,Abromowitch M,Sandlund JT, et al. MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma. Leukemia. 1993; 7: 187191.
  • 33
    Reiter A,Schrappe M,Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in 3 consecutive Berlin-Frankfurt-Munster group studies. JClin Oncol. 1994; 12: 899908.
  • 34
    Sandlund JT,Downing JR,Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med. 1996; 334: 12381248.
  • 35
    Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980; 7: 332339.
  • 36
    Murry DJ,Sandlund JT,Stricklin LM,Rodman JH. Pharmacokinetics and acute renal effects of continuously infused carboplatin. Clin Pharmacol Ther. 1993; 54: 374380.
  • 37
    Kaplan E,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 38
    Peto R,Pike MC,Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977; 35: 139.
  • 39
    Laver JH,Kraveka JM,Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005; 23: 541547.
  • 40
    Reiter A,Schrappe M,Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999; 94: 32943306.
  • 41
    Mann G,Yakisan E,Schrappe M, et al. Diffuse large B-cell lymphomas in childhood and adolescence: favorable outcome with a Burkitt's lymphoma directed therapy in trial NHL-BFM-90-a report of the BFM group. Med Pediatr Oncol. 1997; 29: 358.
  • 42
    Patte C,Michon J,Behrendt H, et al. B-cell large cell lymphoma in children, description and outcome when treated with the same regimen as Burkitt. Ann Oncol. 1996; 7. Abstract 92.
  • 43
    Michon J,Patte C,Landman-Parker J, et al. Mediastinal large B cell lymphoma. Results of the French Society of Pediatric Oncology (SFOP) LMB89 Protocol. Med Pediatr Oncol. 1997; 29: 441.
  • 44
    Patte C,Auperin A,Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007; 109: 27732780.
  • 45
    Woessmann W,Seidemann K,Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005; 105: 948958.
  • 46
    Fisher RI,Gaynor ER,Dahlberg S, et al. Comparison of a standard regimen (CHOP) with 3 intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 10021006.
  • 47
    Kremer LC,van Dalen EC,Offringa M,Voute PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol. 2002; 13: 503512.
  • 48
    Lipshultz SE,Colan SD,Gelber RD,Perez-Atayde AR,Sallan SE,Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991; 324: 808815.
  • 49
    Sorensen K,Levitt G,Bull C,Chessells J,Sullivan I. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J Clin Oncol. 1997; 15: 6168.
  • 50
    Nysom K,Holm K,Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998; 16: 545550.
  • 51
    Krischer JP,Epstein S,Cuthbertson DD,Goorin AM,Epstein ML,Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997; 15: 15441552.
  • 52
    Lipshultz SE,Lipsitz SR,Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995; 332: 17381743.
  • 53
    Hudson MM,Rai SN,Nunez C, et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol. 2007; 25: 36353643.
  • 54
    Kremer LC,van der Pal HJ,Offringa M,van Dalen EC,Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol. 2002; 13: 819829.
  • 55
    van Dalen EC,van der Pal HJ,Kok WE,Caron HN,Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer. 2006; 42: 31913198.
  • 56
    Lipshultz SE,Lipsitz SR,Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005; 23: 26292636.
  • 57
    Meistrich ML,Wilson G,Brown BW,da Cunha MF,Lipshultz LI. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. Cancer. 1992; 70: 27032712.
  • 58
    Tebbi CK,London WB,Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007; 25: 493500.
  • 59
    Hutchison RE,Berard CW,Shuster JJ,Link MP,Pick TE,Murphy SB. B-cell lineage confers a favorable outcome among children and adolescents with large-cell lymphoma: a Pediatric Oncology Group study. J Clin Oncol. 1995; 13: 20232032.